Cambridge Cognition Holdings PLC GBP1.37 million of new eCOA contracts (3674G)
March 17 2020 - 3:00AM
UK Regulatory
TIDMCOG
RNS Number : 3674G
Cambridge Cognition Holdings PLC
17 March 2020
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition wins GBP1.37m of new eCOA contracts
Cambridge Cognition Holdings plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce that the Company has won a contract for three phase II
studies with a new pharmaceutical client (the "Client"). The
Directors believe these studies, which have an aggregate value to
the Company of GBP1.37 million, demonstrate significant progress
for the Company in delivering its strategy of combining the sale of
CANTAB(TM) cognitive assessments with additional electronic
clinical outcome assessments (eCOA). Contract delivery is expected
to be over a two year period.
The Company will provide the Client with a single vendor
solution for all three studies, managing the procurement of
licences, device provision, CANTAB(TM) cognitive assessments, a
centralised platform for data acquisition and storage, as well as
trial management services. The Client and the Company will
additionally collaborate on the design and testing of a new
cognitive task for use in clinics. The contract also includes the
provision of one-to-one training for study sites, as well as the
licensing of eCOA instruments. These additional services, which
amount to 44% of the contract value, will be provided by a
subcontractor to Cambridge Cognition.
The three studies will include a total of 180 patients - 60 per
clinical group - with the overall objective being to track early
cognitive changes and motor signals associated with the drug being
delivered. By delivering CANTAB(TM) cognitive assessments and eCOA
questionnaires and scales all one platform, the Client will be able
to sensitively, efficiently and securely monitor three distinct
clinical populations.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"We are pleased to welcome another pharmaceutical partner to our
growing client base, using our innovative digital health
technologies. This is the second partnership that has been secured
on the strength of launching our enhanced eCOA solution in 2019;
underlining the importance of continuing to invest in developing
our digital solutions."
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Nick Walters, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Manasa Patil (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company
developing digital health products to better understand, detect and
treat conditions affecting brain health. The company's software
products assess cognitive health in patients worldwide to improve
clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare
industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTBQLLFBXLLBBZ
(END) Dow Jones Newswires
March 17, 2020 03:00 ET (07:00 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2023 to Apr 2024